Heidelberg-based biopharmaceutical company Exciva, which develops clinical-stage therapies for agitation and other neuropsychiatric symptoms in Alzheimer’s disease and related dementias, has raised €51 million in a Series B funding round, as Vestbee was told.
- Launched in 2016 by Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva develops clinical-stage treatments for neuropsychiatric symptoms associated with Alzheimer’s disease and other dementias.
- The company focuses on agitation and aggression, combining clinically validated CNS-active compounds into novel therapeutic approaches designed to improve efficacy and safety compared with existing options.
- Exciva advances its candidates through a translational research model that integrates molecular science, behavioral pharmacology and clinical development, with its lead programs currently in mid-stage clinical testing.
Details of the deal
- The Series B round was co-led by Gimv and EQT Life Sciences, with participation from Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, and existing investors Andera Partners and LBBW.
“As founding investors of Exciva, we are thrilled to see this significant fundraising led by a blue-chip set of European investors. We look forward to continuing our support as the company advances its differentiated drug candidate into a large phase 2/3 trial targeting agitation in Alzheimer’s disease, a condition with a major unmet medical need," claims Raphaël Wisniewski, Partner at Andera Partners.
- The firm will use the fresh funding primarily to finance a Phase 2 clinical trial of Deraphan for the treatment of agitation in patients with Alzheimer’s disease across Europe, the UK, the US, and Canada.
“We are delighted that we could attract funding from both existing and new investors. This confirms that our product is highly promising. If the results of the phase 2 trial are positive, it will be a significant step forward in symptomatic treatment options for patients with Alzheimer’s disease," explains François Conquet, CEO of Exciva.
